Official announcements from Yap Inc. — partnerships, awards, funding, and more.
Press Release
Yap signs a service agreement with Italy's Icarus — adapting an AI that takes the first call at medical institutions for Japan
Yap Inc. has signed a definitive service agreement, dated August 25, 2026, with Icarus S.r.l. (brand name: Icarus Technology), an Italian company providing a voice assistant in which AI answers calls to medical institutions. Following the memorandum of understanding signed on May 28, 2026, Yap now begins the research needed to adapt the service to Japanese healthcare settings. The name for the Japanese market is "Kyoko AI." No launch date in Japan has been decided at this time.
Yap Signs Memorandum of Understanding with Italy's Icarus S.r.l.
Yap Inc. has signed a Memorandum of Understanding (MoU) on a business partnership with Icarus S.r.l. (product brand: Icarus Technology), a company based in Sardinia, Italy. The MoU follows business development meetings in Tokyo, with the support of the Italian Trade Agency (ITA) and Regione Autonoma della Sardegna, and through SusHi Tech Tokyo, hosted by the Tokyo Metropolitan Government, and the venue of Tokyo Innovation Base. Icarus provides a multilingual AI voice assistant that automates patient phone reception for clinics; together the two companies aim to combine this with Yap's healthcare business and AI capabilities to expand in the Japanese market.
Yap Signs Partnership Agreement with Indonesian Digital Biobank Asa Ren
Yap Inc. has signed a business partnership agreement with Asa Ren, an Indonesian digital biobank company. Asa Ren operates Southeast Asia's first AI-powered digital biobank, integrating clinical and genomic data across diverse ethnic groups to advance personalized medicine and drug discovery. The two companies aim to expand awareness and adoption of Asa Ren's digital biobank.
Yap Signs Import Agreement with Bangladesh's UniMed UniHealth — First Bangladeshi Pharma to Enter Japan
Yap Inc. has signed an import agreement with UniMed UniHealth Pharmaceuticals Limited of Bangladesh. The agreement marks the first entry of a Bangladeshi pharmaceutical company into the Japanese market, beginning with Novotin, a biotin-based nutritional supplement.
Healthcare commentary shared by CEO Masaya Yamamoto on NewsPicks.
Platform
Filter by Tag
NewsPicksSeptember 29, 2026
ロンジェビティ産業 ― 「日本の長寿」は集団知か個人商品か
The buzz around a ¥4.1 million-per-month longevity resort on Awaji Island signals that 'Japanese longevity' itself is becoming a premium product—but I think we should be careful about what that framing obscures. Japan's healthy life expectancy was not purchased by individuals through intensive personal programs; it was built through population-wide measures: widespread salt reduction and blood-pressure management, workplace and municipal health screenings, and the accessibility of care under universal insurance. A resort offering dense, individualized intervention is, by design, moving in precisely the opposite direction from what actually produced Japanese longevity. If the offering is marketed under the banner of 'Japanese know-how,' it's worth being explicit about where that lineage genuinely applies and where it ends. The article asks what people seek beyond mere longevity, and here Japan holds no model answer—it is a country already living with the consequences: social isolation among the elderly, and the lived reality that preserving physical function to age 100 means little if roles and connections have been lost along the way. Whether longevity is measured by cellular and biomarker youth alone, or treated as the design of a life that remains worth living over the long run, is a question Japan is compelled to confront firsthand—and that, I believe, is the genuinely distinctive perspective Japan can bring to this conversation.
LongevityHealthy Aging & Public HealthAging Society
The discussion around Kobayashi Pharmaceutical's potential privatization is often framed as corporate restructuring in the wake of the red yeast rice supplement scandal, but it should also be read as a structural issue for the healthcare industry at large. In Japan, the market for OTC drugs and functional foods has expanded while the boundary between the two categories remained blurred, leaving safety management systems and adverse-event reporting mechanisms inadequately developed across the industry, regardless of company size. This incident has exposed those weaknesses, and the question of going public or private should not distract from the more fundamental challenge of redesigning product-safety governance. The logic that privatization—by shielding management from short-term shareholder pressure—could enable deeper structural reform is understandable. However, transparency and disclosure are the bedrock of trust for any healthcare company, and if privatization erodes them, stakeholder risk simply shifts to a different form. The core question is how to rebuild trust with consumers, healthcare professionals, and regulators—and under which governance structure that rebuilding should be designed.
The limitations of a "one-size-fits-all" diet have long been debated in nutritional science, and given individual variation in gut microbiota, genetic polymorphisms, and metabolic responses, it is time to seriously reconsider how crude population-averaged dietary guidelines have always been. That said, reading a $66.9 billion market figure as straightforward validation of precision nutrition may be premature. Even as the costs of wearables and comprehensive omics analysis fall, the technology risks floating in mid-air unless "translators" capable of interpreting data within each person's real-life context can keep pace—meaning that the benefits of individualization will only reach daily life once clinical dietitians, registered nutritionists, and primary care physicians are equipped to work with precision nutrition insights. In Japan, the infrastructure for incorporating dietary intervention evidence into insurance-covered care remains fragile, creating a risk that the out-of-pocket market races ahead on its own. The question of who can actually access precision nutrition must be answered not only as a market-sizing discussion but as a matter of institutional design—and that moment has already arrived.
The reality of measles deaths in the United States—despite the existence of an effective vaccine—should be read not only as a public health issue but as a crisis of social trust. Behind vaccine hesitancy lies more than simple anti-science sentiment: there is an accumulated distrust of medical institutions and government, the spread of misinformation through social media, and the entanglement of certain political narratives. The fact that a state governor publicly criticized the Secretary of Health is telling—it reveals how dysfunction in federal health communication is directly undermining frontline prevention efforts. Japan is not immune to this; sporadic measles cases are reported every year, and regional disparities in vaccination rates and hesitancy within specific communities have been documented here as well. What matters is not only the accuracy of information, but the question of trust design—who delivers the message and how. In moments like these, the roles of family physicians and community public health nurses take on deeper significance. Preventing disease ultimately rests not on systems and statistics alone, but on how we build trust between people.
The evolution of rural drugstores into food-heavy outlets—stocking fresh produce and ready-made meals—may feel out of place to urban dwellers, but viewed through the lens of regional healthcare, it reads as an inevitable development. In areas where supermarkets and grocery stores have withdrawn, pharmacies and drugstores are left with little choice but to serve as the last pillar of daily life infrastructure. This is not merely business diversification; it is a process of consolidating purchasing, health, and community support functions into a single hub. What deserves particular attention is the potential for this model to link food access and health management within the same physical space: if registered dietitians and pharmacists can actively guide food choices, there are meaningful implications for chronic disease prevention and medication adherence. The real question going forward is whether this structural shift can move beyond a simple retail story and become a mechanism for raising health literacy at the community level. At the same time, the challenge of balancing commercial viability with deep local dependency remains. Because these stores are effectively shouldering public-infrastructure roles, the time has come to design deliberate frameworks for collaboration with local governments and healthcare institutions.
Community Health & HealthcareFood Access & Nutrition EnvironmentDrugstore & Retail Policy
The milestone of more than 100,000 centenarians in Japan can be framed statistically as 'the maturing of a longevity society,' but from a healthcare perspective, the more important task is to carefully read the challenges layered within that figure. The fact that women account for 87% of centenarians—a proportion that has barely shifted for years—reflects not simply biological difference but a complex interplay of lifestyle, social roles, and disparities in healthcare access, pointing to meaningful differences in the quality of how people reach old age. Equally concerning is the regional divide: the density of infrastructure supporting elderly people varies sharply between urban and rural areas, meaning that the conditions enabling a person to live to 100 are far from evenly distributed. Questions around community healthcare, home-based care, and the sustainability of long-term care deserve to be revisited every time this statistic is updated. Longevity is not a destination; the real question is how to design the quality of life that follows. We have entered a stage that demands a genuinely substantive conversation—one in which individuals, communities, and institutions work together to rebuild the systems that support aging, going well beyond fiscal debates about social security.